36/100
A decline of cognitive abilities is a part of normal human ageing. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
36/100
It may be that risk and protective factors vary with age, however, in the absence of prophylactic treatment it seems likely that the maintenance of a healthy lifestyle may represent the best option with regard to the prevention of dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Greater adherence to MedDiet and frequency of consumption of some foods were associated with better scores in several CF tests in elderly individuals with high risk of MS living in a rural community. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although it is well established that physical activity increases mitochondrial content in muscle, the molecular mechanisms underlying this process have only recently been elucidated. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Significant progress has been made in understanding the neurobiological mechanisms through which exercise protects and restores the brain. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
AMPK (AMP-activated protein kinase) is a phylogenetically conserved fuel-sensing enzyme that is present in all mammalian cells. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
Physical activity and antidepressant treatment have each separately been of significant interest for the management of Alzheimer's disease (AD); particularly the behavioral problems associated with this dementing disorder. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
No clear consensual definition regarding frailty seems to emerge from the literature after 30 years of research in the topic, and a large array of models and criteria has been proposed to define the syndrome. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
We conclude that structural and molecular prerequisites for activity-dependent plasticity are preserved in mutant mice with an AD-like pathology. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting the elderly population. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) afflicts more than 5.4 million Americans and ranks as the most common type of dementia (Thies and Bleiler, 2011), yet effective pharmacological treatments have not been identified. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Multicomponent interventions can improve physical functioning and BADL in elderly subjects regardless of the stage of dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Most chronic diseases--such as cancer, cardiovascular disease (CVD), Alzheimer disease, Parkinson disease, arthritis, diabetes and obesity--are becoming leading causes of disability and death all over the world. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Environmental enrichment (EE) increases levels of novelty and complexity, inducing enhanced sensory, cognitive and motor stimulation. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
Dementia is a complex human disease. The incidence of dementia among the elderly population is rising rapidly worldwide. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
Poor physical function and muscle strength coexisted with cognitive impairment. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
35/100
Age-related cognitive decline, characterized by memory loss, attention deficits, and reduced executive function, remains a major public health challenge, with limited pharmaceutical interventions offering symptomatic relief. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Five themes emerged. Both older adults and adult children had partial knowledge of dementia and were able to list learning new things and social activities as cognitively stimulating activities. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
35/100
[Purpose] We evaluated the effects of a multicomponent intervention for pre-frail and frail older adults and assessed changes in cognitive function and body composition to explore frailty reversibility. [Participants and Methods] A total of 51 community-dwelling older adults aged 70 years or older were classified into the Robust (n=28) and Prefrail/Frail groups (n=23) using the Kihon Checklist. 1 key finding →
Participants: 28 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The program was effective, as evidenced by the multidimensional health gains achieved. 4 key findings →
Participants: 504 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
34/100
Recent discoveries indicating that the brain retains its ability to adapt and change throughout life have sparked interest in cognitive training (CT) as a possible means to postpone the development of dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
=3.40; P=.04). Greater cognitive improvements were associated with younger age, higher functional status, and lower baseline cognitive function. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study aimed to evaluate the effectiveness of the comprehensive dementia prevention application 'MELI' in enhancing cognitive function and alleviating depressive symptoms among older adults.A total of 50 participants aged 60 and older, enrolled in a dementia prevention program operated in Namdong-gu, Incheon, South Korea, were randomly assigned to either an experimental or a control group, with 25 participants in each. 1 key finding →
Participants: 50 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Multidomain lifestyle interventions can improve cognitive function and mobile health technologies can deliver cost-effective interventions. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Age-related upregulation in microRNA (miR)-204 and downregulation in long noncoding RNA (lncRNA) nuclear enriched abundant transcript 1 (NEAT1) were observed to disrupt Ephrin-B1 (EFNB1)/EphB2 interactions, leading to reduced cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway activation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events